Incyte CORP Form 4 insider transactions

Incyte's EVP & Chief Medical Officer, Steven H. Stein, was granted 19,932 employee stock options with an exercise price of $106.21, vesting over three years starting July 2026.

Incyte Corp's EVP, Head of US Oncology, Mohamed Khairie Issa, was granted 14,237 employee stock options with an exercise price of $106.21.

Incyte Corp's EVP, GM of Dermatology US, Matteo Trotta, was granted 8,542 employee stock options with an exercise price of $106.21.

Incyte's Principal Accounting Officer, Tray Thomas, was granted 2,425 employee stock options with an exercise price of $106.21, vesting over three years.

Incyte's EVP & Chief Scientific Officer, Patrick A. Mayes, was granted 4,218 employee stock options with an exercise price of $106.21.

Incyte's EVP, Head of Tech. Operations, Michael James Morrissey, received a grant of 7,426 restricted stock units and subsequently disposed of 429 shares to cover tax withholding obligations.

Mohamed Khairie Issa, Incyte's EVP, Head of US Oncology, reported the sale of 10,856 common shares and a tax-related withholding of 8,264 shares, both executed under a Rule 10b5-1 plan.

Incyte's EVP and Chief Medical Officer, Steven H. Stein, sold 15,634 shares of common stock for $101.7 per share under a pre-arranged 10b5-1 trading plan.

Incyte Corp's EVP & Chief Medical Officer, Steven H. Stein, disposed of 13,292 shares of common stock to cover tax withholding obligations.

Incyte's EVP of Technology Operations, Michael James Morrissey, disposed of 254 shares of common stock to cover tax withholding obligations related to restricted stock unit settlement.

Incyte Corp. Director Paul J. Clancy acquired 241 shares of common stock at $98.77 per share through a pre-arranged stock incentive plan.

Incyte Corp. Director Edmund Harrigan acquired 245 shares of common stock at $98.77 per share as part of a pre-arranged equity compensation plan.

Julian C. Baker, a director and 10% owner of Incyte Corp, received 328 shares of common stock in lieu of quarterly director retainer fees, as reported in a recent SEC Form 4 filing.

Incyte's Principal Accounting Officer, Tray Thomas, reported planned exercises of stock options and sales of common stock under a 10b5-1 plan.

Incyte's EVP, Head of Tech. Operations, Michael James Morrissey, sold a total of 58,331 shares of common stock in pre-planned transactions on December 16 and 17, 2025.

Incyte's EVP & Chief Scientific Officer, Patrick A. Mayes, sold 5,808 shares of common stock in two transactions under a pre-arranged 10b5-1 trading plan.

Incyte Corp. Director Herve Hoppenot reported a tax-related disposition of 2,843 common shares at $96.7, maintaining a beneficial ownership of 326,803 shares.

Incyte's EVP & Chief Medical Officer, Steven H. Stein, sold a total of 22,664 shares of common stock and had 17,093 shares withheld for taxes in early December 2025, pursuant to a Rule 10b5-1 plan.

Incyte's EVP, Head of Tech. Operations, Michael James Morrissey, reported the disposition of 326 common shares to cover tax withholding obligations related to restricted stock units.

Incyte Corporation's EVP & General Counsel, Richard A. Hoffman, was granted restricted stock units, stock options, and performance shares effective December 1, 2025.

Incyte's Principal Accounting Officer, Tray Thomas, reported the sale of 769 shares of common stock across two transactions in late November 2025.

Incyte's EVP and General Counsel, Sheila A. Denton, exercised stock options and subsequently sold an equal number of common shares on November 17, 2025, under a Rule 10b5-1 plan.

Incyte Corp Director Herve Hoppenot reported the planned sale of 187,500 shares of common stock at $105.46 per share, executed under a pre-arranged 10b5-1 plan.

Incyte's EVP & Chief Medical Officer, Steven H. Stein, exercised stock options and subsequently sold 5,233 shares of common stock for liquidity and diversification.

Incyte's EVP and General Counsel, Sheila A. Denton, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 plan.

Incyte Corp's EVP, Head of Incyte International, Heeson Lee, sold 3,074 shares of common stock for $94.02 per share under a Rule 10b5-1 plan.

Incyte's EVP & General Counsel, Sheila A. Denton, exercised stock options and subsequently sold an equal number of common shares.

Incyte's EVP & General Counsel, Sheila A. Denton, reported exercising stock options and subsequently selling shares, including shares withheld for tax obligations, under a Rule 10b5-1 plan.

Incyte's EVP & Chief Scientific Officer, Patrick A. Mayes, disposed of 1,569 shares of common stock at $86.7 per share to cover tax withholding obligations related to restricted stock units.

Incyte Corp's EVP, Head of Incyte International, Lee Heeson, disposed of 463 common shares to cover tax withholding obligations at a price of $86.7 per share.